Analysis of FOXO1 mutations in diffuse large B-cell lymphoma
- 2 May 2013
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 121 (18) , 3666-3674
Abstract
Diffuse large B-cell lymphoma (DLBCL) accounts for 30% to 40% of newly diagnosed lymphomas and has an overall cure rate of approximately 60%. Previously, we observed FOXO1 mutations in non-Hodgkin lymphoma patient samples. To explore the effects of FOXO1 mutations, we assessed FOXO1 status in 279 DLBCL patient samples and 22 DLBCL-derived cell lines. FOXO1 mutations were found in 8.6% (24/279) of DLBCL cases: 92.3% (24/26) of mutations were in the first exon, 46.2% (12/26) were recurrent mutations affecting the N-terminal region, and another 38.5% (10/26) affected the Forkhead DNA binding domain. Recurrent mutations in the N-terminal region resulted in diminished T24 phosphorylation, loss of interaction with 14-3-3, and nuclear retention. FOXO1 mutation was associated with decreased overall survival in patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (P = .037), independent of cell of origin (COO) and the revised International Prognostic Index (R-IPI). This association was particularly evident (P = .003) in patients in the low-risk R-IPI categories. The independent relationship of mutations in FOXO1 to survival, transcending the prognostic influence of the R-IPI and COO, indicates that FOXO1 mutation is a novel prognostic factor that plays an important role in DLBCL pathogenesis. Key Points Recurrent mutations in FOXO1 affect the DNA binding domain and the T24 phosphorylation site, which disrupt interactions with 14-3-3. Presence of FOXO1 mutations is associated with decreased OS, particularly in DLBCL patients of the low-risk R-IPI categories.Keywords
This publication has 42 references indexed in Scilit:
- Analysis of the coding genome of diffuse large B-cell lymphomaNature Genetics, 2011
- Frequent mutation of histone-modifying genes in non-Hodgkin lymphomaNature, 2011
- 14-3-3σ regulates B-cell homeostasis through stabilization of FOXO1Proceedings of the National Academy of Sciences, 2011
- Foxo1 regulates marginal zone B‐cell developmentEuropean Journal of Immunology, 2010
- A “FOXO” in sight: Targeting Foxo proteins from conception to cancerMedicinal Research Reviews, 2008
- Distinct functions for the transcription factor Foxo1 at various stages of B cell differentiationNature Immunology, 2008
- Foxo1 directly regulates the transcription of recombination-activating genes during B cell developmentNature Immunology, 2008
- OutFOXOing disease and disability: the therapeutic potential of targeting FoxO proteinsTrends in Molecular Medicine, 2008
- FoxOs Are Lineage-Restricted Redundant Tumor Suppressors and Regulate Endothelial Cell HomeostasisCell, 2007
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000